Immunoglobulin E specific for Dermatophagoides pteronyssinus allergens (Der p-specific IgE)

Immunoglobulin E (IgE) antibodies specific for Dermatophagoides pteronyssinus (house dust mite) allergens are the primary mediators of house dust mite-induced allergic diseases. These antibodies are produced by B cells upon sensitization to mite proteins like Der p 1 and Der p 2 and subsequently bind to high-affinity FcεRI receptors on the surface of effector cells, such as mast cells and basophils (Gould & Sutton, Nature, 2008). Upon re-exposure, the allergens cross-link these cell-bound IgE molecules, triggering the immediate release of inflammatory mediators like histamine and leukotrienes, which lead to symptoms of asthma and rhinitis (Gao et al., PubMed, 2021). Therapeutic strategies focus on reducing the activity or presence of these antibodies. Omalizumab, a monoclonal antibody, targets the Fc region of free IgE to prevent it from binding to effector cells (PubChem, 2024). Alternatively, allergen-specific immunotherapy (AIT) involves the controlled administration of mite allergens to shift the immune response from IgE-mediated hypersensitivity toward a tolerant state dominated by IgG4 blocking antibodies (EAACI Guidelines, 2018). This shift reduces the density of allergen-specific IgE on mast cells and basophils over time. Monitoring of specific IgE levels and skin reactivity is essential for managing patients undergoing these treatments.

Other names

House dust mite-specific IgEHDM-specific IgEAnti-Der p IgEDer p 1-specific IgEDer p 2-specific IgE

Omalizumab binds to the Cε3 domain of free IgE, preventing its binding to the high-affinity IgE receptor (FcεRI) on mast cells and basophils. Allergen-specific immunotherapy (AIT) utilizes Dermatophagoides pteronyssinus allergen extracts to induce immune tolerance, characterized by the induction of regulatory T cells and the production of "blocking" IgG4 antibodies that compete with IgE for allergen binding.